000282669 001__ 282669
000282669 005__ 20240229155044.0
000282669 0247_ $$2doi$$a10.1002/mds.29602
000282669 0247_ $$2pmid$$apmid:37675653
000282669 0247_ $$2ISSN$$a0885-3185
000282669 0247_ $$2ISSN$$a1531-8257
000282669 0247_ $$2altmetric$$aaltmetric:153908669
000282669 037__ $$aDKFZ-2023-01815
000282669 041__ $$aEnglish
000282669 082__ $$a610
000282669 1001_ $$00000-0002-5275-0036$$aZhao, Yujia$$b0
000282669 245__ $$aPrediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort.
000282669 260__ $$aNew York, NY$$bWiley$$c2023
000282669 3367_ $$2DRIVER$$aarticle
000282669 3367_ $$2DataCite$$aOutput Types/Journal article
000282669 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1703227555_27741
000282669 3367_ $$2BibTeX$$aARTICLE
000282669 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282669 3367_ $$00$$2EndNote$$aJournal Article
000282669 500__ $$a2023 Dec;38(12):2302-2307
000282669 520__ $$aMetals have been postulated as environmental concerns in the etiology of Parkinson's disease (PD), but metal levels are typically measured after diagnosis, which might be subject to reverse causality.The aim of this study was to investigate the association between prediagnostic blood metal levels and PD risk.A case-control study was nested in a prospective European cohort, using erythrocyte samples collected before PD diagnosis.Most assessed metals were not associated with PD risk. Cadmium has a suggestive negative association with PD (odds ratio [95% confidence interval] for the highest quartile, 0.70 [0.42-1.17]), which diminished among never smokers. Among current smokers only, lead was associated with decreased PD risk (0.06 [0.01-0.35]), whereas arsenic showed associations toward an increased PD risk (1.85 [0.45-7.93]).We observe no strong evidence to support a role of metals in the development of PD. In particular, smoking may confound the association with tobacco-derived metals. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000282669 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000282669 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282669 650_7 $$2Other$$aParkinson's disease
000282669 650_7 $$2Other$$acohort study
000282669 650_7 $$2Other$$ametals
000282669 650_7 $$2Other$$aprospective exposure assessment
000282669 7001_ $$aRay, Anushree$$b1
000282669 7001_ $$aBroberg, Karin$$b2
000282669 7001_ $$aKippler, Maria$$b3
000282669 7001_ $$aLill, Christina M$$b4
000282669 7001_ $$aVineis, Paolo$$b5
000282669 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena A$$b6$$udkfz
000282669 7001_ $$aRodriguez-Barranco, Miguel$$b7
000282669 7001_ $$aChirlaque, María-Dolores$$b8
000282669 7001_ $$aGuevara, Marcela$$b9
000282669 7001_ $$aGómez, Jesús-Humberto$$b10
000282669 7001_ $$aHansen, Johnni$$b11
000282669 7001_ $$aPanico, Salvatore$$b12
000282669 7001_ $$aMiddleton, Lefkos T$$b13
000282669 7001_ $$aMasala, Giovanna$$b14
000282669 7001_ $$aPala, Valeria$$b15
000282669 7001_ $$aVinagre-Aragon, Ana$$b16
000282669 7001_ $$aZibetti, Maurizio$$b17
000282669 7001_ $$aVermeulen, Roel$$b18
000282669 7001_ $$00000-0001-5662-1971$$aPeters, Susan$$b19
000282669 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.29602$$gp. mds.29602$$n12$$p2302-2307$$tMovement disorders$$v38$$x0885-3185$$y2023
000282669 909CO $$ooai:inrepo02.dkfz.de:282669$$pVDB
000282669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000282669 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000282669 9141_ $$y2023
000282669 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-11$$wger
000282669 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000282669 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000282669 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000282669 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000282669 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2023-10-24
000282669 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000282669 980__ $$ajournal
000282669 980__ $$aVDB
000282669 980__ $$aI:(DE-He78)C020-20160331
000282669 980__ $$aUNRESTRICTED